Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
) said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
Gilead’s late-stage study evaluated the safety and efficacy of five-day and 10-day dosing durations of remdesivir in hospitalized patients. The study did not have a placebo comparison. “The mortality in the remdesivir trials has generally been lower for both control and intervention groups than other trials and other real world cohorts I’ve seen,” Gellad said in an email.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks Cut Losses After Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of DeathStocks cut losses today after Gilead said that the remdesivir coronavirus treatment reduces the risk of death by skleb1234
Read more »
Gilead says remdesivir coronavirus treatment reduces risk of death in severely sick patientsThe findings show that 7.6% of patients treated with remdesivir died compared with 12.5% of patients in the analysis who did not receive remdesivir treatment.
Read more »
Stocks Cut Losses After Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of DeathThe market opened flat as investors weigh a recent spike in new cases with positive vaccine news.
Read more »
A new Gilead analysis indicates remdesivir can reduce death but company says finding 'requires confirmation'Shares of Gilead Sciences Inc. undefined gained 2.0% in premarket trading on Friday after the drugmaker disclosed findings from a new analysis of previously...
Read more »
Gilead says remdesivir coronavirus treatment reduces risk of death
Read more »
Gilead begins testing inhalable form of remdesivir for COVID-19Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.
Read more »